Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...
Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.
Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.
The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.
Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...
The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...
Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven ...
It’s easy to understand why more than 90% of patients in psychedelic trials know they received the study drug. Even when trials use a drug in the comparison group that produces a noticeable effect, ...
An AI chemistry agent asked a fairly ordinary question: Did a particular molecule have a known hepatobiliary side effect? The agent chose a relevant tool to look for the answer. Then it fed the tool a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results